NATCO Pharma Shares in Focus as Board Approves Investment Up to ₹1,400 Crore in South African Subsidiary

NATCO Pharma Limited has announced two major financial decisions. The company's Board has approved an investment of up to ₹1,400 crore in its wholly owned subsidiary, NATCO Pharma South Africa Proprietary Limited.   

Additionally, NATCO will execute a ₹1,069 crore transaction to acquire additional shares in South Africa-based Adcock Ingram Holdings Proprietary Limited, raising its total stake from 35.75% to 49% to expand its regional footprint, as per the company's exchange filings.  

Details of the Investment 

On July 8, 2026, NATCO Pharma's Board of Directors approved the acquisition of 19,618,825 shares in Adcock Ingram at ZAR 92.50 per share.  

This transaction elevates NATCO's stake from 35.75% to 49%, with a total investment cost of ZAR 1,814,741,312.50, equivalent to ₹1,069 crore at the prevailing exchange rate. 

Adcock Ingram, a South African pharmaceutical company established in 1890, operates across 4 segments: Prescription, Consumer, OTC, and Hospitals. The company reported a turnover of ZAR 9,760 million for the year ending June 2025. 

NATCO's Investment in South Africa 

In addition to increasing its stake in Adcock Ingram, NATCO Pharma plans to invest up to ₹1,400 crore in its wholly-owned subsidiary, Natco Pharma South Africa Proprietary Limited. This investment aims to enhance NATCO's presence in the African continent. 

Adcock Ingram's Market Position 

Adcock Ingram holds a 10% market share in the private sector and is a leader in the OTC pharmaceutical market in South Africa. The company is also the largest supplier of hospital and critical care products in the region. 

Read More: Apollo Micro Systems Share Price Falls Over 5%; Board Approves ₹3,322.23 Crore Fundraise! 

Regulatory Approvals and Timeline 

The acquisition is subject to customary closing conditions and compliance with the Foreign Exchange Management Act governed by the Reserve Bank of India, along with necessary regulatory approvals in South Africa. The transaction is expected to be completed by the end of July 2026. 

NATCO Pharma Share Price Performance 

As of July 08, 2026, at 12:22 PM, NATCO Pharma share price on NSE was trading at ₹980.85, down by 0.34% from the previous closing price. 

Conclusion 

NATCO Pharma's investment of ₹1,069 crore to increase its stake in Adcock Ingram to 49% reflects its strategic focus on expanding its presence in South Africa. The acquisition aligns with NATCO's objective to enhance its geographic footprint and profitability in the pharmaceutical sector. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.